Compare BSAC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | RPRX |
|---|---|---|
| Founded | 1977 | 1996 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 19.5B |
| IPO Year | 2002 | 2020 |
| Metric | BSAC | RPRX |
|---|---|---|
| Price | $33.14 | $49.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $33.00 | ★ $51.40 |
| AVG Volume (30 Days) | 396.3K | ★ 2.6M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.95% | 1.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.78 |
| Revenue | N/A | ★ $2,378,193,000.00 |
| Revenue This Year | $37.15 | $38.63 |
| Revenue Next Year | $7.52 | $4.73 |
| P/E Ratio | ★ $14.40 | $27.87 |
| Revenue Growth | N/A | ★ 5.06 |
| 52 Week Low | $22.77 | $31.84 |
| 52 Week High | $37.72 | $50.08 |
| Indicator | BSAC | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 63.40 |
| Support Level | $31.78 | $35.34 |
| Resistance Level | $33.36 | N/A |
| Average True Range (ATR) | 0.84 | 0.91 |
| MACD | -0.14 | 0.07 |
| Stochastic Oscillator | 23.96 | 86.30 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.